^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:HER2 Negative Breast Cancer
    Drug:docetaxel (Tubulin polymerization promoter, Microtubule stabilizer)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Invasive Breast Cancer: HER-2 negative...Other Recommended Regimens…Docetaxel…
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

    Excerpt:
    ...- HR negative and HER 2 negative....
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment

    Excerpt:
    ...- HER2 negative status (i.e. IHC score 0 or 1+, or IHC score 2+ and FISH/SISH/CISH negative), -...
    Trial ID:
    ASTER 70s
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

    Excerpt:
    ...- The primary tumor and metastases (if re-biopsy was performed) were both HER2-negative;...
    Trial ID:
    NCT05430399
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients

    Excerpt:
    ...Hormonal Receptor (HR) negative defined as < 1% positive cells by Immunohistochemistry (IHC) for both Estrogen Receptor (ER) and Progesterone Receptor (PgR), and HER2 negative defined as in situ hybridization (ISH) negative or IHC 0 or 1+ in the absence of ISH (...
    Trial ID:
    EDALINE
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

    Excerpt:
    ...- Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC)...
    Trial ID:
    NCT00703326
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer

    Excerpt:
    ...- HER2-negative disease...
    Trial ID:
    NCT00852332
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer

    Excerpt:
    ...HER2-negative...
    Trial ID:
    NCT03147963
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

    Excerpt:
    ...- Patients with HER-2 negative disease with documented disease progression after (neo)adjuvant treatment with an anthracycline-based chemotherapy regimen....
    Trial ID:
    NCT00471159
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer

    Excerpt:
    ...- Histologically- or cytologically-proven adenocarcinoma of the breast that is HER2 negative....
    Trial ID:
    NCT01038804
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Prospective, open, multicenter, single arm clinical study of atapatinib combined with docetaxel in the treatment of HER2 negative breast cancer with a first-line to three line chemotherapy failure

    Excerpt:
    ...1) aged 18-70 year old female patients; 2) at least one target can be defined according to the evaluation criteria of solid tumor efficacy (RECIST 1.1), and there is no radiation therapy (or other local treatment) in the target area unless radiotherapy or other local treatment is completed; 3) the recurrence and metastatic HER -2 negative breast cancer was confirmed by pathology; the HER-2 negative criterion was HER-2 (- / + +). ...
    Trial ID:
    ChiCTR1800016103